drugset / Trial / NCT03510546

Effect of Pyridostigmine (Mestinon) on Muscle Strength in Myasthenia Gravis

NCT03510546

RandomizedCrossoverDouble-blindTreatment

Summary

A randomized, placebo-controlled, double-blinded cross-over study evaluating and quantifying the effect of pyridostigmine on muscle strength and symptoms in Myasthenia Gravis (MG)

Timeline

Start
2018-04-09
Primary completion
2020-08-31
Completion
2021-08-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Pyridostigmine Small molecule 60 mg

Indications